The FDA has approved the first DNA test to help healthcare professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus antiviral therapy.
While a patient is undergoing anti-CMV therapy, a clinician can use the COBAS AmpliPrep/COBAS TaqMan CMV Test to look for changes in a patient's CMV viral load. A significant decrease in viral load from one test to the next may indicate that a particular therapy is effective, while an increase or no change may indicate the need for a different therapy.
CMV is a common virus that can cause severe diseases such as pneumonia or colitis in people with weakened immune systems, including solid organ transplant patients.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
While a patient is undergoing anti-CMV therapy, a clinician can use the COBAS AmpliPrep/COBAS TaqMan CMV Test to look for changes in a patient's CMV viral load. A significant decrease in viral load from one test to the next may indicate that a particular therapy is effective, while an increase or no change may indicate the need for a different therapy.
CMV is a common virus that can cause severe diseases such as pneumonia or colitis in people with weakened immune systems, including solid organ transplant patients.
More Articles on Infections:
TRICARE Patients See Fewer MRSA Infections
Consumer Reports Releases Hospital Safety Ratings
How Hospitals' Data Transparency Can Spur Quality Improvement
